Today we learn that generics giant Mylan has entered into a partnership with India-based Biocon to focus on insulin analog biosimilars:
Under the terms of this collaboration, Mylan will have the rights to develop and market Biocon’s Glargine (the generic version of Sanofi’s Lantus®), Lispro (the generic version of Eli Lilly’s Humalog®) and Aspart (the generic version of Novo Nordisk’s NovoLog®).
Mylan and Biocon will share development, capital and certain other costs to bring the products to market. Mylan will have exclusive commercialization rights in the U.S., Canada, Australia, New Zealand, the European Union and the European Free Trade Association countries through a profit share arrangement with Biocon. Mylan will have co-exclusive commercialization rights with Biocon in certain other markets around the world.
This is consistent with one of the panel discussions at BioEurope in November, in which Amgen and other major biotech companies said that very few companies will succeed in the biosimilars space, at least in the near term. The most successful companies will need the large-scale access to cell lines, manufacturing, marketing, and distribution assets which are unique to biologics, and quite different from your traditional oral/parenteral products.
Related articles
